Radio-immunotherapy for B-cell non-Hodgkin lymphoma
Visser, O.J.; Zijlstra, J.M.; van Dongen, G.A.M.S.; Huijgens, P.C.
Nederlands Tijdschrift Voor Geneeskunde 149(42): 2324-2328
2005
ISSN/ISBN: 0028-2162 PMID: 16261710 Document Number: 585536
Radio-immunotherapy is a new treatment modality for patients with B-cell non-Hodgkin lymphoma. In radio-immunotherapy, a therapeutic radionuclide is coupled to a monoclonal antibody directed against a tumour-specific or tumour-associated antigen. Biodistribution studies and dosimetry are used in the planning of radio-immunotherapy. Clinical studies, notably in patients with indolent non-Hodgkin lymphoma, have demonstrated the clinical feasibility and efficacy of this treatment. The use of a high dose ofradio-immunotherapy in combination with (high-dose) chemotherapy and peripheral stem-cell transplantation constitutes a supplemental treatment for patients who respond insufficiently or not at all to standard therapy. The exact place of radio-immunotherapy in the treatment of patients with non-Hodgkin lymphomas is not yet clear.